2018 Blood Pressure Disorders Drug Development Pipeline Review - ResearchAndMarkets.com

September 17, 2018

DUBLIN--(BUSINESS WIRE)--Sep 17, 2018--The “Blood Pressure Disorders Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

This report Blood Pressure Disorders Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.


Which companies are the most active within the pipeline for blood pressure disorders? Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened within this field?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Mentioned

A1M Pharma AB Aerogen Ltd Anavex Life Sciences Corp AnGes Inc Bioblue Technologies Inc Biogen Inc Biolab Farmaceutica Ltda BioRestorative Therapies Inc Chiesi Farmaceutici SpA Chong Kun Dang Pharmaceutical Corp Chugai Pharmaceutical Co Ltd CJ HealthCare Corp Complexa Inc Corion Biotech Srl Gilead Sciences Inc GlaxoSmithKline Plc H. Lundbeck AS Insmed Inc Insys Therapeutics Inc Lee’s Pharmaceutical Holdings Ltd Novartis AG Omeros Corp Orion Corporation Peloton Therapeutics Inc Pfizer Inc PhaseBio Pharmaceuticals Inc Pulmokine Inc rEVO Biologics Inc Shanghai Pharmaceutical Co Ltd Takeda Pharmaceutical Co Ltd Target Medicals LLC The Medicines Company Theracos Inc XuanZhu Pharma Co Ltd Yuhan Corp For more information about this report visit https://www.researchandmarkets.com/research/8rl624/2018_blood?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005590/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Hematological Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/17/2018 01:06 PM/DISC: 09/17/2018 01:06 PM


Update hourly